Amarin Corp Plcuk (AMRN) Other Non-Current Liabilities (2010 - 2026)
Amarin Corp Plcuk (AMRN) reported Other Non-Current Liabilities of $11.1 million for Q1 2026, down 4.47% year-over-year from $11.6 million in Q1 2025, and up 1.52% quarter-over-quarter from $11.0 million in Q4 2025.
Amarin Corp Plcuk (AMRN) Other Non-Current Liabilities (2010 - 2026) Analysis & Trends
Amarin Corp Plcuk (AMRN) has 17 years of Other Non-Current Liabilities data on file, last reported at $11.1 million in Q1 2026.
- Other Non-Current Liabilities for Q1 2026 came in at $11.1 million, down 4.47% year-over-year; the trailing twelve-month figure through Mar 2026 was $11.1 million (down 4.47% YoY), and the FY2025 annual result was $11.0 million, down 4.75% from the prior year.
- Other Non-Current Liabilities advanced to $11.1 million in Q1 2026 per AMRN's latest filing, from $11.0 million in the prior quarter.
- Over five years, Other Non-Current Liabilities peaked at $12.0 million in Q3 2025 and troughed at $7.2 million in Q2 2023.
- A 5-year average of $9.5 million and a median of $9.3 million in 2024 frame the typical range for Other Non-Current Liabilities.
- The sharpest annual moves came in 2022 and 2023: Other Non-Current Liabilities surged 81.25% in 2022, then slipped 25.0% in 2023.
- A 5-year view of Other Non-Current Liabilities shows it stood at $8.2 million in 2022, then climbed by 10.47% to $9.1 million in 2023, then climbed by 26.89% to $11.5 million in 2024, then declined by 4.75% to $11.0 million in 2025, then grew by 1.52% to $11.1 million in 2026.
- Business Quant data shows AMRN's Other Non-Current Liabilities at $11.1 million in Q1 2026, $11.0 million in Q4 2025, and $12.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn |
| 10 | Amarin Corp Plcuk | 5.84 Bn | 5.66 Bn | 17.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11.12 Mn |
| Dec 31, 2025 | 10.96 Mn |
| Sep 30, 2025 | 11.96 Mn |
| Jun 30, 2025 | 11.92 Mn |
| Mar 31, 2025 | 11.64 Mn |
| Dec 31, 2024 | 11.50 Mn |
| Sep 30, 2024 | 9.47 Mn |
| Jun 30, 2024 | 9.34 Mn |
| Mar 31, 2024 | 9.20 Mn |
| Dec 31, 2023 | 9.06 Mn |
| Sep 30, 2023 | 7.27 Mn |
| Jun 30, 2023 | 7.16 Mn |
| Mar 31, 2023 | 8.61 Mn |
| Dec 31, 2022 | 8.21 Mn |
| Sep 30, 2022 | 9.70 Mn |
| Jun 30, 2022 | 7.64 Mn |
| Mar 31, 2022 | 7.49 Mn |
| Dec 31, 2021 | 7.65 Mn |
| Sep 30, 2021 | 5.35 Mn |
| Jun 30, 2021 | 5.53 Mn |